INT110348

From wiki-pain
Revision as of 07:12, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 2003
Last Reported 2010
Negated 0
Speculated 3
Reported most in Body
Documents 28
Total Number 44
Disease Relevance 22.39
Pain Relevance 4.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) plasma membrane (Dpp4)
Anatomy Link Frequency
plasma 3
colon 2
pancreatic beta cells 2
brain 1
blood 1
Dpp4 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 529 99.90 Very High Very High Very High
Dynorphin 7 99.84 Very High Very High Very High
bradykinin 15 98.80 Very High Very High Very High
rheumatoid arthritis 11 98.62 Very High Very High Very High
substance P 20 98.32 Very High Very High Very High
cytokine 37 98.04 Very High Very High Very High
antagonist 127 95.56 Very High Very High Very High
Neuropeptide 40 93.80 High High
tolerance 201 92.80 High High
Inflammatory marker 11 92.32 High High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 2594 99.92 Very High Very High Very High
Pressure And Volume Under Development 86 99.88 Very High Very High Very High
Hypoglycemia 756 99.80 Very High Very High Very High
Chronic Sinusitis 11 98.64 Very High Very High Very High
Rheumatoid Arthritis 11 98.62 Very High Very High Very High
Weight Gain 118 98.40 Very High Very High Very High
Targeted Disruption 92 98.16 Very High Very High Very High
Alopecia 14 97.32 Very High Very High Very High
Weight Loss 194 96.76 Very High Very High Very High
Anaemia 14 96.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor.
Negative_regulation (down-regulated) of peptidase IV in immature T-cell associated with dynorphin
1) Confidence 0.46 Published 2003 Journal Life Sci. Section Title Doc Link 12738031 Disease Relevance 0 Pain Relevance 0.24
RESULTS: CD26 inactivation induced a three-fold decrease in circulating endopeptidase activity while that found in brain extracts was normal, albeit very weak.
Negative_regulation (inactivation) of CD26 in brain
2) Confidence 0.43 Published 2006 Journal Behav. Brain Res. Section Body Doc Link 16154213 Disease Relevance 0 Pain Relevance 0
METHODS: Using CD26-/- mice resulting from targeted inactivation of the gene, we examined the consequences of a DPP-IV defect on behavioural response to nociceptive stimuli and concentration of the pain modulator peptides substance P (SP) and endomorphin 2, two DPP-IV substrates.
Spec (examined) Negative_regulation (defect) of DPP-IV
3) Confidence 0.43 Published 2006 Journal Behav. Brain Res. Section Body Doc Link 16154213 Disease Relevance 0 Pain Relevance 0
Because NPY is a better substrate for DPP4, Y2 tone was predicted to be amplified by a selective DPP4 inhibitor.
Negative_regulation (inhibitor) of DPP4
4) Confidence 0.37 Published 2008 Journal Nutrition Section Body Doc Link PMC2572019 Disease Relevance 0.05 Pain Relevance 0.15
The DPP4 inhibitor, compound 3, was a gift from Dr.
Negative_regulation (inhibitor) of DPP4
5) Confidence 0.27 Published 2008 Journal Nutrition Section Body Doc Link PMC2572019 Disease Relevance 0.09 Pain Relevance 0
DPP4 inhibitors are clinically important because they also prolong the half-life of incretin hormones, GLP-1 and GLP-2 [21], both of which lower blood glucose in a glucose-dependent manner.
Negative_regulation (inhibitors) of DPP4 in blood
6) Confidence 0.27 Published 2008 Journal Nutrition Section Body Doc Link PMC2572019 Disease Relevance 0.15 Pain Relevance 0.03
Co-administering an ACE inhibitor and a DPP-4 inhibitor (as an antidiabetic agent) increases significantly the risk of angioedema.
Negative_regulation (inhibitor) of DPP-4 associated with pressure and volume under development
7) Confidence 0.27 Published 2010 Journal Rev Med Suisse Section Abstract Doc Link 20196430 Disease Relevance 0.71 Pain Relevance 0.27
In practice, the combination of an insulin sensitizer (metformin or a TZD) with a GLP-1 analog or a DPP-4 inhibitor minimizes the risk of hypoglycemia and weight gain, and can help to achieve and maintain glycemic goals long term.
Negative_regulation (inhibitor) of DPP-4 associated with hypoglycemia and weight gain
8) Confidence 0.22 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.81 Pain Relevance 0
DPP-4 inhibition can also prolong the action of endogenous peptides, such as pituitary adenylate cyclase-activating peptide, growth hormone-releasing hormone, peptide YY, neuropeptide Y, and substance P, as well as several other chemokines.
Negative_regulation (inhibition) of DPP-4 in pituitary associated with chemokine, neuropeptide and substance p
9) Confidence 0.22 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.79 Pain Relevance 0.14
Selectivity of alogliptin for DPP-4 inhibition is defined as a > 10,000 greater affinity for the DPP-4 enzyme than for competing DPP enzymes, such as DPP-2, 8, and 9.
Negative_regulation (inhibition) of DPP-4
10) Confidence 0.22 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.88 Pain Relevance 0.09
In a mechanism of action study, DeFronzo et al10 compared sitagliptin, a DPP-4 inhibitor, with exenatide, a GLP-1 agonist.
Negative_regulation (inhibitor) of DPP-4 associated with agonist
11) Confidence 0.22 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.40 Pain Relevance 0.15
GLP-1 agonists (exenatide and liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, saxagliptin, vildagliptin, and alogliptin) improve insulin secretion by pancreatic beta cells, and decrease the elevated rate of glucagon secretion by alpha cells.
Negative_regulation (inhibitors) of DPP-4 in pancreatic beta cells associated with agonist
12) Confidence 0.22 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.82 Pain Relevance 0.05
Despite the relatively recent advent of GLP-1 agonists and DPP-4 inhibitors, evidence has rapidly accumulated to support their efficacy and safety in the management of T2DM, as well as their potential for improving cardiovascular and ?
Negative_regulation (inhibitors) of DPP-4 associated with diabetes mellitus and agonist
13) Confidence 0.20 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.88 Pain Relevance 0.08
,146 inhibition of DPP-4 may have adverse effects on immune function.
Negative_regulation (inhibition) of DPP-4
14) Confidence 0.20 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 1.00 Pain Relevance 0.24
Given the comparable outcomes of the use of GLP-1 agonists and DPP-4 inhibitors in T2DM for many parameters, their cost-effectiveness is an important issue.
Negative_regulation (inhibitors) of DPP-4 associated with diabetes mellitus and agonist
15) Confidence 0.20 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.49 Pain Relevance 0.08
[Angioedema during ACE and DPP-4 inhibition].
Negative_regulation (inhibition) of DPP-4 associated with pressure and volume under development
16) Confidence 0.20 Published 2010 Journal Rev Med Suisse Section Title Doc Link 20196430 Disease Relevance 0.62 Pain Relevance 0.26
These results are consistent with our finding that DPP-IV inhibition, which prolongs GLP-1 action, did not affect the mucosal Gpr119 responses in mouse colon.
Negative_regulation (inhibition) of DPP-IV in colon
17) Confidence 0.19 Published 2010 Journal Cell Metabolism Section Body Doc Link PMC2890049 Disease Relevance 0 Pain Relevance 0.22
Mucosal responses to Gpr119 agonists do not involve enteric nerves (or NPY) and are not amplified by blockade of DPP-IV activity.


Negative_regulation (blockade) of DPP-IV in enteric nerves associated with agonist
18) Confidence 0.19 Published 2010 Journal Cell Metabolism Section Body Doc Link PMC2890049 Disease Relevance 0 Pain Relevance 0.12
Furthermore, neither Y2 antagonism with BIIE0246 nor DPP-IV inhibition had any effect on Gpr119 responses in human colon (Figure 2E), again, as observed in WT mouse colon.
Negative_regulation (inhibition) of DPP-IV in colon
19) Confidence 0.19 Published 2010 Journal Cell Metabolism Section Body Doc Link PMC2890049 Disease Relevance 0 Pain Relevance 0.22
GLP-1 agonists (exenatide and liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, saxagliptin, vildagliptin, and alogliptin) improve insulin secretion by pancreatic beta cells, and decrease the elevated rate of glucagon secretion by alpha cells.
Negative_regulation (inhibitors) of peptidase-4 in pancreatic beta cells associated with agonist
20) Confidence 0.19 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.82 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox